CA2453372A1 - Methylation resistant vectors - Google Patents

Methylation resistant vectors Download PDF

Info

Publication number
CA2453372A1
CA2453372A1 CA002453372A CA2453372A CA2453372A1 CA 2453372 A1 CA2453372 A1 CA 2453372A1 CA 002453372 A CA002453372 A CA 002453372A CA 2453372 A CA2453372 A CA 2453372A CA 2453372 A1 CA2453372 A1 CA 2453372A1
Authority
CA
Canada
Prior art keywords
vector
host cell
cytosine
nucleotide sequence
donor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002453372A
Other languages
English (en)
French (fr)
Inventor
Bengt Widegren
Leif G. Salford
Bertil Persson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geneinvent BBL AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2453372A1 publication Critical patent/CA2453372A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CA002453372A 2001-07-27 2002-07-08 Methylation resistant vectors Abandoned CA2453372A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0102627A SE518759C2 (sv) 2001-07-27 2001-07-27 Vektorer motståndskraftiga mot metylering
SE0102627-7 2001-07-27
PCT/SE2002/001121 WO2003012112A1 (en) 2001-07-27 2002-07-08 Methylation resistant vectors

Publications (1)

Publication Number Publication Date
CA2453372A1 true CA2453372A1 (en) 2003-02-13

Family

ID=20284952

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002453372A Abandoned CA2453372A1 (en) 2001-07-27 2002-07-08 Methylation resistant vectors

Country Status (6)

Country Link
EP (1) EP1419257A1 (sv)
JP (1) JP2004536616A (sv)
CA (1) CA2453372A1 (sv)
MX (1) MXPA04000651A (sv)
SE (1) SE518759C2 (sv)
WO (1) WO2003012112A1 (sv)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
KR102004559B1 (ko) 2011-08-30 2019-07-26 아스텍스 파마수티컬스, 인크. 데시타빈 유도체 제제
FR2981946B1 (fr) * 2011-10-28 2015-02-20 Lfb Biotechnologies Unites de transcription et leur utilisation dans des vecteurs d'expression (yb2/0)
JP6768722B2 (ja) 2015-07-02 2020-10-14 大塚製薬株式会社 凍結乾燥医薬組成物
BR112020002280A2 (pt) 2017-08-03 2020-07-28 Otsuka Pharmaceutical Co., Ltd. composto farmacológico e métodos purificação do mesmo

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552277A (en) * 1994-07-19 1996-09-03 The Johns Hopkins University School Of Medicine Genetic diagnosis of prostate cancer
WO1996012008A1 (en) * 1994-10-13 1996-04-25 Merck & Co., Inc. Synthesis of methylase-resistant genes
US6783933B1 (en) * 1999-09-15 2004-08-31 The Johns Hopkins University School Of Medicine CACNA1G polynucleotide, polypeptide and methods of use therefor
AU8021500A (en) * 1999-10-13 2001-04-23 Johns Hopkins University School Of Medicine, The Methods of diagnosing and treating hepatic cell proliferative disorders
EP1224303A2 (en) * 1999-10-18 2002-07-24 Emory University Tms1 compositions and methods of use

Also Published As

Publication number Publication date
SE0102627L (sv) 2002-11-19
MXPA04000651A (es) 2004-10-27
EP1419257A1 (en) 2004-05-19
JP2004536616A (ja) 2004-12-09
SE518759C2 (sv) 2002-11-19
SE0102627D0 (sv) 2001-07-27
WO2003012112A1 (en) 2003-02-13

Similar Documents

Publication Publication Date Title
CN112266411B (zh) 一种新型冠状病毒疫苗及其应用
EP0929564B1 (en) High level expression of proteins
RU2757675C2 (ru) Молекулы новых искусственных нуклеиновых кислот
JP4434479B2 (ja) 標的の細胞および組織においてタンパク質を選択的に発現するための核酸配列および方法
AU610057B2 (en) Mammalian interleukin-4
ES2574584T3 (es) Transfección estable sin suero y producción de proteinas humanas recombinantes en líneas celulares humanas
CN114787357A (zh) 用于编辑靶标rna的添加了功能性区域的反义型指导rna
IE66307B1 (en) Recombinant human endothelial cell growth factor
JP4525863B1 (ja) 高生産性細胞の樹立のための発現ベクター及び高生産性細胞
CS125091A3 (en) Polypeptides
EP2534255B1 (en) Method of reducing glycosylation of proteins, processes and proteins thereof
US20030045497A1 (en) Methylation resistant vectors
EP3954774A1 (en) Rna site-directed editing using artificially constructed rna editing enzymes and related uses
KR102598130B1 (ko) 글로빈 유전자 클러스터의 조절 요소를 포함하는 진핵생물 발현 벡터
CA2453372A1 (en) Methylation resistant vectors
KR0123892B1 (ko) 인간의 콜로니 자극 인자
EP2128261B1 (en) A recombinant adenovirus comprising recombinant khp53 gene and preparation method and uses thereof
KR20230000471A (ko) 비천연 5'-비번역 영역 및 3'-비번역 영역 및 그의 용도
KR20040020817A (ko) 당쇄화된 사람 인터페론 알파 동종체
US7842493B2 (en) Cell lines having enhanced cell longevity and protein expression
JP6150143B2 (ja) 薬剤選択融合遺伝子を含む高生産性細胞の樹立のための発現ベクター
RU2761378C1 (ru) Ген, кодирующий открытую рамку считывания М-сегмента ККГЛ, и рекомбинантная конструкция, обеспечивающая экспрессию структурных гликопротеинов вируса Крым-Конго геморрагической лихорадки
CN113061168B (zh) 一种截短的发热伴血小板减少综合征病毒Gn蛋白及其应用
EP1278874B1 (en) Hybrid protein and vector encoding the same for inhibition of angiogenesis
JP4642865B2 (ja) 新規制御エレメントを含むベクター

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead